The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, 3052, VIC, Australia.
MRC Cognition and Brain Sciences Unit, University of Cambridge, Cambridge, CB2 7EF, UK.
EBioMedicine. 2024 Nov;109:105416. doi: 10.1016/j.ebiom.2024.105416. Epub 2024 Oct 30.
Pathogenic missense variants in the essential synaptic vesicle protein synaptotagmin-1 (SYT1) cause a neurodevelopmental disorder characterised by motor delay and intellectual disability, hyperkinetic movement disorder, episodic agitation, and visual impairments. SYT1 is the presynaptic calcium sensor that triggers synchronous neurotransmitter release. We have previously shown that pathogenic variants around the calcium-sensing region of the critical C2B domain decrease synaptic vesicle exocytosis in neurons.
Here, we have used cultured hippocampal neurons transfected with SYT1-pHluorin to examine how variants within the C2A and C2B domain of SYT1 impact evoked exocytosis.
We show that recently identified variants within the facilitatory C2A domain of the protein (L159R, T196K, E209K, E219Q), as well as additional variants in the C2B domain (M303V, S309P, Y365C, G369D), share an underlying pathogenic mechanism, causing a graded and variant-dependent dominant-negative impairment in exocytosis. We establish that the extent of evoked exocytosis observed in vitro in the presence of SYT1 variants correlates with neurodevelopmental impacts of this disorder. Specifically, the severity of motor and communication impairments exhibited by individuals harbouring these variants correlates with multiple measures of exocytic efficiency.
Together, this suggests that there is a genotype-function-phenotype relationship in SYT1-associated neurodevelopmental disorder, centring impaired evoked neurotransmitter release as a common pathogenic driver. Moreover, this points toward a direct link between control of neurotransmitter release and development of adaptive functions, providing a tractable target for therapeutic amelioration.
Australian National Health and Medical Research Council, UK Medical Research Council, Great Ormond Street Hospital Children's Charity, University of Melbourne.
突触融合蛋白 1(SYT1)中必需的突触小泡蛋白的致病性错义变异导致一种神经发育障碍,其特征为运动延迟和智力残疾、多动运动障碍、阵发性激越和视觉障碍。SYT1 是触发同步神经递质释放的突触前钙传感器。我们之前已经表明,关键 C2B 结构域钙敏区域周围的致病性变异会降低神经元中的突触小泡胞吐作用。
在这里,我们使用转染了 SYT1-pHluorin 的培养海马神经元来研究 SYT1 的 C2A 和 C2B 结构域内的变异如何影响诱发的胞吐作用。
我们表明,该蛋白的促进性 C2A 结构域内最近鉴定的变异(L159R、T196K、E209K、E219Q)以及 C2B 结构域中的其他变异(M303V、S309P、Y365C、G369D)具有共同的潜在致病机制,导致胞吐作用的分级和变异依赖性显性负性损伤。我们确定了在存在 SYT1 变异的情况下体外观察到的诱发胞吐作用的程度与该疾病的神经发育影响相关。具体而言,携带这些变异的个体表现出的运动和沟通障碍的严重程度与多个胞吐效率测量相关。
总的来说,这表明 SYT1 相关神经发育障碍存在基因型-功能-表型关系,以诱发神经递质释放受损为共同的致病驱动因素。此外,这表明在控制神经递质释放和适应性功能发展之间存在直接联系,为治疗改善提供了一个可行的目标。
澳大利亚国家健康与医学研究理事会、英国医学研究理事会、大奥蒙德街儿童医院慈善基金会、墨尔本大学。